Logo, Madera BioSciences


Ed Iwanowicz, Ph.D.
Founder & CEO
Edwin Iwanowicz, PhD is founder and the CEO of Madera BioSciences, which he started in 2008. He plays a key role in the management and governance of Madera and is also a partner at Forward Medical Science Partners, a fund within Forward Ventures in San Diego, CA. In this role, Ed together with Stan Fleming, a founding member of Forward Ventures, is advancing a new business model for drug discovery and development.
Prior to his current position, Ed was VP and US head of the CREATE organization at J&J where he oversaw small molecule drug discovery technologies in the US. Previously, he was Head of Chemical Sciences and VP for the Novartis Institutes for BioMedical Research site at Emeryville, CA. Subsequent to the Novartis purchase of Chiron, Ed was VP, Chemical Sciences for Chiron supporting all chemical research activities for the Biopharmaceutical/Vaccine/ Blood Testing business units. In this role, he restructured and managed an organization central to the strategic plans for Chiron's growth. Prior to Chiron, Ed was VP, Chemistry at Triad Therapeutics, a venture-backed biotechnology company focused on new methods of structure-based drug design. He helped lead the turn around of research, establishing a leading p38 inhibitor program that was partnered with Novartis AG in a deal valued in excess of $70M. Prior to his role at Triad, Ed spent 13 years at the Bristol-Myers Squibb (BMS) Institute. While at BMS, Ed had roles of increasing responsibility. He was a founding member of the Immunology Division and managed programs leading to the first two clinical candidates. Ed also contributed to programs yielding clinical candidates for the treatment of cardiovascular and oncological diseases including Dasatinib®. Ed began his industrial career as staff scientist at the GE Central Research investigating interface dynamics of biphasic mixtures of polymeric materials. He has authored over 70 publications and patents.  Ed holds a B.S. in Chemistry from the University of Massachusetts, Amherst and a Ph.D. in Chemistry from the University of Rochester.

David Kimball, Ph.D.
Senior Scientific Advisor, Drug Discovery

David has over 25 years experience in the discovery and development of small molecule drug candidates in multiple therapeutic areas.  He is currently consulting Chief Scientific Officer at Hydra Biosciences, a biopharmaceutical company based in Cambridge, MA which is focused on applying its understanding of Transient Receptor Potential (TRP) ion channels to the discovery of drugs for pain, inflammation and respiratory disease. He is also professor of Pharmacy at Rutgers University.

Prior to joining Hydra in 2008, Dr. Kimball was Senior Vice President of Research at Pharmacopeia and was responsible for all drug discovery research and non-clinical development as well as research alliances.  During that period, Pharmacopeia progressed compounds towards clinical trials in inflammatory disease, cachexia, hypertension and diabetic nephropathy. From 2001-2007, Dr. Kimball served as Vice President of Medicinal Chemistry at Lexicon Pharmaceuticals, in Princeton, New Jersey.  While at Lexicon, David built a small molecule discovery organization of over 75 chemists, including medicinal, analytical, computational, process research and development, library synthesis and outsourcing chemistry.  Starting from the novel drug targets discovered by its genetics platform, Lexicon Pharmaceuticals' small molecule pipeline includes compounds in clinical trials for diabetes, irritable bowel syndrome, carcinoid syndrome, rheumatoid arthritis and glaucoma.

David began his career at the Squibb Institute for Medical Research, ultimately serving as Research Fellow at the Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, New Jersey.  During his tenure at BMS, he led several significant drug discovery and development efforts that culminated in clinical compounds, including inhibitors of cyclin-dependent kinase 2 for oncology, inhibitors of the serine protease thrombin for the treatment of arterial and venous thrombosis and long-acting calcium channel blockers for the treatment of hypertension and angina.

Dr. Kimball has lectured widely on drug discovery and has been an Associate Member of the Graduate Faculty at Rutgers University School of Pharmacy since 1989.  He earned his Ph.D. in Organic Chemistry/Chemical Biology from the State University of New York at Stony Brook in the lab of Professor Francis Johnson.  He is the author of over 20 patents and 40 peer-reviewed publications.


Board Members


Paul Howard

Paul Howard is a Partner and founder of Mediphase Venture Partners. Mr. Howard concentrates his efforts on the Life Sciences companies in the portfolios. He has invested in over 25 private companies including Tularik, Exelixis, CV Therapeutics, Cubist, Rosetta Inpharmatics, Dyax, LJL Biosytems, Ilypsa, Relypsa, Serenex, Supplemental Healthcare, Wellpartner and Tetraphase. Mr. Howard serves on the Board of Directors of Supplemental Health Care and Serenex.??Prior to founding Mediphase Venture Partners, Mr. Howard was a Senior Vice President at Hambrecht & Quist Capital Management in Boston from 1992-1999, where he was responsible for managing the fund's biotechnology investments. From 1983-1990 Mr. Howard was a Senior Technical Sales Executive for the Miles Biotechnology Division of Bayer A.G.??Mr. Howard earned an A.B. from Bowdoin College in 1981, an M.S. from the University of Massachusetts, Amherst in 1983, and an S.M. from the Sloan School of Management at M.I.T. in 1992.

Ed Iwanowicz, Ph.D.
Founder & CEO




Amir Hoveyda, Ph.D.

Dr. Hoveyda is the Joseph T. and Patricia Vanderslice Millennium Professor of Chemistry and Chair of the Department of Chemistry at Boston College. He is a widely-sought advisor to biotech and pharma companies for his multifaceted approaches to using chemistry to solve drug discovery problems.

He and his group discover, design and develop new catalysts for chemical synthesis that are easily prepared, are stable to air and moisture and can be recycled, introducing efficient new chiral catalysts that can be used to synthesize important enantiomerically pure compounds for the preparation of biologically and medicinally active agents. The Hoveyda group's focus is on transformations that are truly important (such as conjugate additions and olefin metathesis), but cannot be catalyzed efficiently by existing methods. They are interested in complex molecule total synthesis (testing their catalysts), study of reaction mechanism (how do the catalysts work?) and new approaches to catalyst discovery (combinatorial chemistry).

Dr. Hoveyda received his B.A. from Columbia University, his Ph.D. in Chemistry from Yale University in the lab of Stuart Schreiber and was an American Cancer Society Postdoctoral Fellow at Harvard University with David Evans prior to being recruited to Boston College. Dr. Hoveyda has more than 170 peer-reviewed publications and numerous patents.

Stan Fleming

Mr. Fleming is a veteran of early-stage venture capital investing and has helped raise and manage six venture funds totaling more than $500M and has served on the boards of 19 venture-backed companies. He has extensive experience in all aspects of venture management and finance.

Mr. Fleming is managing partner of Forward Ventures, which he co-founded in 1993. In this capacity he served as the initial president and CEO of Triangle Pharmaceuticals (acquired by Gilead , Actigen and Gen Quest/Corixa (now parts of GSK), and CombiChem (acquired by DuPont). In addition, Mr. Fleming has significant experience as a board member for numerous companies. Mr. Fleming serves as a director of CONNECT, San Diego's support organization for the academic-to-early-stage community, and is a past president of the Biotechnology Venture Investors Group. He earned his B.A. from Amherst College and his M.B.A. from the UCLA Graduate School of Management.